News

Solazyme--the company that produces oil for cosmetics, industrial equipment and airplanes from genetically modified algae force-fed on sugar--held its IPO today and so far it's doing well.

Researchers have developed a self-nanoemulsifying drug delivery system of flutamide, an antiandrogen drug for the treatment of prostate cancer, and characterized the particle size, self-nanoemulsification and dissolution enhancement.

In this study, a refined time interval versus dose theory was tested. The resulting in vivo exposures based on altering frequency and doses were compared, and significant impacts were found.

Exelixis, Inc. announces the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology.

ProteaBio Europe SAS, announces that the company, in partnership with Mayoly-Spindler, has successfully completed a Phase I/IIA human clinical trial for their MS1819 recombinant Lipase.

Publication of a Phase II randomized, double-blind, placebo-controlled clinical trial evaluating the Company's lead product candidate, oral talactoferrin.

Data demonstrate strong immunogenicity of the HIV-1 vaccine both in serum and at the mucosal sites.

Company selected to receive the award based on the international success of the Gyros immunoassay platform.

Trial could generate future alternative treatment for multiple myeloma.

Dr. Hill, is a Board Certified High Complexity Laboratory Director, Board Certified Embryology Laboratory Director and member of the American Association of Bioanalysts.